Concepedia

Nathan Enas

NE

Statistics

Publications

16

Citations

1.3K

H-Index

15

Active since

1990

Affiliations

Eli Lilly (United States)(Current)

Eli Lilly (United Kingdom)

University of Chicago

Cancer Research Center

Vanderbilt University Medical Center

Nathan Enas is an author at Eli Lilly (United States) specializing in medicine, pharmacotherapy, and pharmacology.

Top concepts

Publications per year

1990–2016

16

Publications

16

An investigational new drug treatment program for patients with gemcitabine

Anna Maria Storniolo, Nathan Enas, Cheryl A. Brown et al. · Cancer · 1999 · 261 citations

Phase II Study of Enzastaurin, a Protein Kinase C Beta Inhibitor, in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Michael J. Robertson, Brad S. Kahl, Julie M. Vose et al. · Journal of Clinical Oncology · 2007 · 230 citations

Phase I Dose Escalation and Pharmacokinetic Study of Enzastaurin, an Oral Protein Kinase C Beta Inhibitor, in Patients With Advanced Cancer

Michael A. Carducci, Luna Musib, Merrill S. Kies et al. · Journal of Clinical Oncology · 2006 · 173 citations

Rabeprazole in Treatment of Acid Peptic Diseases (Results of Three Placebo-Controlled Dose-Response Clinical Trials in Duodenal Ulcer, Gastric Ulcer, and Gastroesophageal Reflux Disease (GERD))

M. L. Cloud, Nathan Enas, Thomas J. Humphries et al. · Digestive Diseases and Sciences · 1998 · 116 citations

, , +7

Randomization by minimization for unbalanced treatment allocation

Baoguang Han, Nathan Enas, Damian McEntegart · Statistics in Medicine · 2009 · 112 citations

1–5 of 16